Endovascular Simulation Specialist Mentice Appoints Chief Clinical Officer
Mentice, the world leading provider of endovascular performance solutions, today announced the appointment of Dr. David J. Ballard as Chief Clinical Officer and Executive Vice President of the Mentice Group. Dr. Ballard was previously appointed an independent member of the Mentice board of directors in October 2018.
“I am excited to join the Mentice executive team, in addition to continuing to engage my existing role on the Mentice board,” says Dr. Ballard. “I have spent the last couple of months educating myself on the opportunities to leverage Mentice solutions to reduce harm to patients, and to make health care more affordable. We have excellent opportunities to make significant contributions towards achieving both these objectives in partnership with healthcare systems across the world.”
Dr. Ballard (M.D., M.S.P.H., Ph.D., F.A.C.P.) is a health care executive with proven expertise in improving healthcare value and organizational financial performance, while providing international thought leadership. Dr. Ballard was recognized by Becker’s Hospital Review as one of the top 50 experts leading the field of patient safety in 2015, 2016, 2017 and 2018.
A past president of the International Society for Quality in Health Care, Dr. Ballard in 2008 received the Distinguished Alumnus Award from the University of North Carolina School of Medicine. Widely recognized as a scholar in health care quality and value, his two books on health care quality leadership have received Shingo Awards for their contributions to operational excellence.
Dr. Ballard served the past 19 years as Chief Quality Officer of Baylor Scott & White Health, the largest health care system in Texas. He has also served in leadership roles at Emory University (1994-1999), University of Virginia (1991-1994) and the Mayo Clinic. He holds degrees in economics, epidemiology and medicine from the University of North Carolina where he was a John Motley Morehead Scholar. Dr. Ballard trained in internal medicine at the Mayo Clinic and served from 1986-91 on the Mayo staff as Consultant, Associate Professor and Head of the Section of Health Services Evaluation, where he now serves as Healthcare Policy Section Editor for the Mayo Clinic Proceedings. Dr. Ballard is a member of the Chancellor’s Global Leadership Council at the University of North Carolina where he is also Adjunct Professor of Health Policy and Management in the UNC Gillings School of Global Public Health.
“I’m thrilled to welcome Dr. Ballard to our team,” says Goran Malmberg, Group CEO of Mentice. “Dr. Ballard will help drive our engagement with health systems, and I cannot think of a better person for this role. Mentice has a unique technology and a market-leading position with premier medical device corporations and academic institutes worldwide. We believe the largest opportunity for our solutions is within the field of continuous practice and with leading health systems—areas where we are just beginning.”
Mentice is the world leader in virtual reality‐based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and pre-procedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. For more information about Mentice, visit www.mentice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005063/en/
Contact information
For more information:
Stacy Hammar, Marketing Coordinator
+46
(0) 31 339 94 94
stacy.hammar@mentice.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X19.6.2025 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618511573/en/ [Murata Manufacturing Co., Ltd.] New Chip Ferrite Beads for Automotive In recent years, the use of high-frequency wireless communication in the automotive sector has increased. It is primarily used for content distribution for navigation, audio and other infotainment systems. Improving sensitivity and noise suppression in these advanced high-frequency commu
AV and UAS Denmark Establish Strategic Partnership to Advance Allied UAS Capabilities in Europe18.6.2025 23:30:00 EEST | Press release
AeroVironment, Inc. (“AV”) (NASDAQ: AVAV) today announced it has signed a Memorandum of Understanding (MOU) with Hans Christian Andersen Aiport in Odense, Denmark–home to the UAS Denmark Test Center–to explore joint utilization of the center’s expansive airspace and advanced test facilities. The agreement aims to leverage UAS Denmark’s strategic range and infrastructure to support AV’s uncrewed aircraft system (UAS) demonstration operations, mission training, and customer integration activities across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618380337/en/ JUMP 20 executes a seamless landing on a moving ship (Photo: AV) The collaboration is expected to enable joint research and development (R&D) initiatives and accelerate the growth of the UAS Denmark Test Center as a regional epicenter for advanced UAS innovation, evaluation, and operational readiness. "This MOU represents a significant milestone in expa
Stone Harbor Investment Partners Introduces Emerging Markets Climate Impact Debt Fund18.6.2025 23:05:00 EEST | Press release
Stone Harbor Investment Partners, an investment manager of Virtus Investment Partners, Inc. (NYSE: VRTS), has launched the Stone Harbor Emerging Markets Climate Impact Debt (Bloomberg: STHEMDI) (the “Fund”), a UCITS fund classified as Article 9 under the Sustainable Finance Disclosure Regulation (SFDR) that addresses decarbonization efforts occurring in Emerging Markets (EM) while seeking to deliver attractive long-term total returns for investors. The Fund invests in sustainable debt issued with proceeds dedicated to environmental activities, assets, projects or expenditures, with social bonds also permissible, of EM corporate, sovereign, quasi-sovereign and supranational issuers in hard currency. The Fund, with a sustainable objective to promote the transition towards an environmentally and socially sustainable economy, seeks to outperform the J.P Morgan EM Credit Green, Social and Sustainability Bond Diversified Index (GESSIE EM Credit Div USD Hedged). "Stone Harbor has incorporated
Incyte Announces FDA Approval of Monjuvi ® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma18.6.2025 22:39:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615896694/en/ MONJUVI logo "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without substantial increase in side effects. Based on the data from the inMIND trial of Monjuvi, today’s approval brings to this patient population the first CD-19 and CD20-targeted immunotherapy combination and a potential new treatment standard,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “This second U.S. approval for Monjuvi reinforces our commitment to advancing innovation for the lymp
Bureau Veritas Accelerates its LEAP | 28 Strategy Execution and Evolves its Executive Committee18.6.2025 19:00:00 EEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618391984/en/ Hinda Gharbi, CEO Bureau Veritas Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People - and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom